No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Heron Therapeutics, Inc. is a biotechnology firm dedicated to developing innovative therapeutic solutions for significant unmet patient needs. At the heart of its pipeline is the proprietary Biochronomer drug delivery system. This technology enables the sustained release of various short-acting pharmacological agents, maintaining therapeutic levels for several days to weeks following a single administration. Currently available products include: SUSTOL (granisetron): An extended-release injectable formulated to prevent acute and delayed nausea and vomiting stemming from moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide regimens. CINVANTI (aprepitant): An intravenous antiemetic, acting as a substance P/neurokinin-1 receptor antagonist, used to prevent acute and delayed nausea and vomiting induced by both highly and moderately emetogenic cancer chemotherapy. Its robust development pipeline includes: ZYNRELEF: A dual-acting local anesthetic, delivering a fixed-dose combination of bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. HTX-019: An investigational therapeutic aimed at preventing postoperative nausea and vomiting. HTX-034: Currently in a Phase Ib/II clinical study with bunionectomy patients, designed for managing postoperative pain. Founded in 1983, the company initially operated as A.P. Pharma, Inc. before adopting the name Heron Therapeutics, Inc. in January 2014. Its corporate headquarters are situated in San Diego, California.
www.herontx.comNo one on the platform currently holds 0J4V.L.
No tracked institution reports a position in 0J4V.L as of their last filing.
No one on the platform has traded 0J4V.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 7.4% | 11.8% | ||||
| Profit Margin % | -13.0% | -106.8% | -1534.1% | |||
| Free Cash Flow Margin % | -18.0% | -91.9% | -1231.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $148M | -3.9% | $-0.13 | $-0.13–$-0.13 | — | 1 |
| 2027 | $146M | -1.6% | $-0.11 | $-0.11–$-0.11 | — | 1 |
| 2028 | $161M | +10.0% | $-0.06 | $-0.06–$-0.05 | — | 1 |
| 2029 | $177M | +10.4% | $0.01 | $0.00–$0.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $-0.01 | $-0.03 | -500.0% |
| 2026-05-11 | $-0.02 | $-0.04 | -71.5% |
| 2026-02-26 | $-0.02 | $-0.02 | +0.0% |
| 2025-11-04 | $-0.01 | $-0.10 | -566.7% |
| 2025-08-08 | $-0.01 | $-0.02 | -100.0% |
| 2025-05-06 | $-0.01 | $0.01 | +260.5% |
| 2025-02-27 | $-0.03 | $0.02 | +178.3% |
| 2024-11-12 | $-0.04 |
| $-0.03 |
| +20.8% |
| +2.89% |
| $93M |
| — |
| 0HX7.LAdicet Bio, Inc. | $9.16 | +0.55% | $48M | — |
| 0I0X.LCodexis, Inc. | $1.33 | -3.62% | $119M | — |
Source: Financial Modeling Prep · peers by sector/industry